Keyphrases
Cancer Cell Lines
100%
Cisplatin
100%
Protein Farnesyltransferase
100%
Farnesyltransferase Inhibitor
100%
SCH66336
100%
Synergistic Effect
16%
Antiproliferative Activity
16%
Additive Effect
16%
Pancreatic Adenocarcinoma
8%
Anticancer Agents
8%
Breast
8%
Antagonism
8%
Colon
8%
Drug Effects
8%
5-fluorouracil (5-FU)
8%
Apoptosis
8%
Polypeptide
8%
Post-translational Modification
8%
Antineoplastic Drugs
8%
Clinical Testing
8%
Synergism
8%
Adenocarcinoma Cells
8%
Flow Cytometry
8%
MCF-7
8%
DNA Lesions
8%
Colony Formation Assay
8%
Cell Cycle Distribution
8%
Non-small Cell Lung Cancer Cells
8%
Glioblastoma Cell Lines
8%
A549 Cells
8%
A549
8%
BxPC-3
8%
HCT116
8%
Melphalan
8%
T98G
8%
Platinum-DNA Adduct
8%
Drug Sequencing
8%
Immunology and Microbiology
Antiproliferative Activity
100%
Cancer Cell Line
100%
Cell Line
50%
Synergism
50%
Colon
50%
Cancer Cell
50%
Protein Processing
50%
DNA Damage
50%
Tumor Cell Line
50%
Cell Cycle
50%
DNA Adduct
50%
Programmed Cell Death
50%
Biochemistry, Genetics and Molecular Biology
Farnesyltransferase
100%
Cancer Cell
100%
Cisplatin
100%
Antiproliferative Activity
33%
DNA Adduct
16%
Clinical Study
16%
Colon
16%
Posttranslational Modification
16%
Anticancer
16%
Enzyme
16%
DNA Damage
16%
Cell Cycle
16%
Melphalan
16%
Fluorouracil
16%
Flow Cytometry
16%
Programmed Cell Death
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
100%
Malignant Neoplasm
100%
Protein Farnesyltransferase Inhibitor
100%
Lonafarnib
100%
Preclinical Study
8%
Clinical Study
8%
Flow Cytometry
8%
Synergism
8%
Non Small Cell Lung Cancer
8%
Glioblastoma
8%
Pancreas Adenocarcinoma
8%
Polypeptide
8%
Protein Farnesyltransferase
8%
Melphalan
8%
Neoplasm
8%
Fluorouracil
8%
Anticancer Drug
8%
Neuroscience
Cisplatin
100%
Cell Line
100%
Farnesyltransferase Inhibitor
100%
Melphalan
16%
A549 Cell
16%
Antineoplastic Drugs
16%
Polypeptide
16%
Cell Cycle
16%
DNA Damage
16%
Protein Farnesyltransferase
16%
Fluorouracil
16%
Posttranslational Modification
16%
DNA Adduct
16%
Flow Cytometry
16%
Programmed Cell Death
16%